

What to look forward to in GaBi Journal, 2012, issue 2

Professor Philip Walson, MD

It is my pleasure to introduce the second edition of *GaBi Journal* which contains a number of interesting articles. Professors Benjamin and Kearns present a review of advances in paediatric drug development and labelling, see pages 54–55. This follows on my prior comments about how generics and biosimilars may fail to meet the needs of children [1].

Other original articles discuss a wide range of topics including the lessons learned from the launch of generic clopidogrel (by Dr Christoph Baumgärtel et al., pages 58–68); how generic drug use has improved prescribing practices in a number of countries (by Dr Brian Godman et al., pages 69–83); the role of public–private partnerships in promoting access to generics and biosimilars (by Timothy Mackey and Professor Bryan Liang, pages 84–88); a medicine agency's view of some of the lessons learned from the introduction of the generic 'blockbuster' drug clopidogrel (by Dr Christoph

Baumgärtel, pages 89–91); an overview on the impact of pharmaceutical pricing and reimbursement policies on generics uptake in 29 European countries (by Dr Sabine Vogler, pages 93–100); and a brief overview of the successful Dutch generics substitution system (by Dr Leonora Grandia and Professor Arnold G Vulto, pages 102–103).

There are also three articles prepared by our editors. One reviews the regulatory issues concerning EU rules on pharmacovigilance (pages 56–57), another one discusses how EMA risk management plans (page 104) could increase consumer confidence in generics or biosimilars and the final article discusses how biosimilars could provide at least a partial solution to the rapidly increasing cost of effective but extremely expensive oncology treatments (page 104).

The publisher and I hope you will enjoy this issue, that you will provide feedback,



positive or negative, on the journal or any of these articles. We also hope you will both submit manuscripts and encourage others to do the same.

Reference

1. Walson P. Generic and therapeutic orphans. *Generics and Biosimilars Initiative Journal (GaBi Journal)*. 2012;1(1):39–41. doi: 10.5639/gabij.2012.0101.010

Professor Philip Walson, MD
Editor-in-Chief, GaBi Journal

GaBi Journal - Call for Papers

www.gabi-journal.net



The mission of *GaBi Journal (Generics and Biosimilars Initiative Journal)* is to provide an independent, high quality, authoritative, and peer reviewed platform for the publication of scientific articles concerning any aspect of the research into and development of cost-effective medicines, irrespective of their source.

The scope of *GaBi Journal* is broad and of interest and relevance to professionals active in clinical practice, pharmaceutical science, and policy.

Manuscripts on all aspects of generic and biosimilar medicines covering areas in clinical, fundamental, technical, manufacturing, bioprocessing, economic and social aspects of pharmaceuticals and therapeutics are welcome. In addition, high quality work submitted in other formats, for example, scientific and evidence-based commentaries, may also be considered.

GaBi Journal is supported by the appointment of an International Editorial Advisory Board and an experienced Editorial Board. All manuscripts submitted to *GaBi Journal* are subject to a rigorous peer review process by international experts in the field. The language for the journal is English and manuscripts should be submitted in English. The *GaBi Journal* Instructions for Authors are available on the website (www.gabi-journal.net), where the journal is freely available. Prospective authors are

invited to submit work for consideration for *GaBi Journal*. You are encouraged to discuss your ideas for manuscripts with the Editor-in-Chief, Professor Philip Walson.